S85 Clinical Impact of Vedolizumab Treatment in Patients With Ulcerative Colitis: Evidence from a Real-World Study in Mexico
Bibliographic record
Abstract
Background: Ulcerative colitis (UC) is a chronic inflammatory disease that primarily affects the colonic mucosa, significantly impairing patient’s quality of life. Vedolizumab (VDZ), a humanized monoclonal antibody, targets the α4β7 integrin on leukocytes, inhibiting their interaction with mucosal addressin cell adhesion molecule 1 (MAdCAM-1) and thereby restricting lymphocyte migration to intestinal tissue. VDZ is indicated for moderate to severe UC in patients who have not responded to conventional therapies or tumor necrosis factor-α antagonists and has demonstrated efficacy as a first-line treatment for UC. However, real-world data on VDZ’s effectiveness in Latin America and Mexico is limited. This study aims to assess the impact of VDZ treatment over a 12-week period in UC patients by evaluating both clinical and biochemical parameters. Methods: A cross-sectional, analytical study was conducted involving 27 patients from the Inflammatory Bowel Disease Clinic at the General Hospital of Mexico “Dr. Eduardo Liceaga,” who were diagnosed with UC and treated with VDZ. Data collected included demographic information, disease characteristics, extraintestinal manifestations, and biochemical markers such as C-reactive protein (CRP) levels and fecal calprotectin (FCP). Disease activity was measured using the Truelove and Witts scale. Descriptive statistics summarized the demographic and clinical characteristics of the patients. Continuous variables were presented as means with standard deviations or medians with interquartile ranges, as appropriate. Paired t-tests or Wilcoxon signed-rank tests were used to compare clinical and biochemical parameters before and after treatment, depending on data distribution. A significance level of p < 0.05 was used, and 95% confidence intervals (CIs) were calculated for mean differences (∆). Results: The study cohort was predominantly male (59.3%), with a mean age of 40.11 ± 13.28 years. According to the Montreal classification, 66.7% of patients had pancolitis (E3). Notably, 96.3% of patients had no previous exposure to biological therapies. After 12 weeks of treatment, there was a significant reduction in the Truelove and Witts score from 13.4 ± 2.72 to 9.9 ± 1.4 (∆ = -3.5, 95% CI: -4.6 to -2.4, p < 0.001) and in fecal calprotectin levels, which decreased from 1559 (449 - 2200) to 256 (58.1 - 586) (∆ = -1303, 95% CI: -1750 to -856, p < 0.001). Conversely, CRP levels did not exhibit a significant change. Conclusions: Vedolizumab treatment over a 12-week period significantly improved both clinical and biochemical parameters in UC patients, as evidenced by reductions in the Truelove and Witts score and fecal calprotectin levels. These findings underscore the effectiveness and safety of VDZ as a first-line therapy for UC, particularly in patients without prior exposure to biological treatments. This study provides valuable insights into the application of VDZ in Latin America and Mexico, where real-world data is scarce.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.003 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".